Application of Cocarnit in complex treatment of patients with diabetic polyneuropathy in outpatient practice

Background. Diabetes is one of the global problems of modern healthcare. Diabetic distal symmetric polyneuropathy occurs among 30-80% of diabetic patients, is accompanied by severe pain syndromes, reduces quality of life, and is associated with increased mortality. Blood glucose control is not enough to prevent the development and progression of diabetic polyneuropathy (DPN). The search for new drugs for the treatment of DPN is relevant. Objective. Evaluation of the effect of complex therapy, including the drug Cocarnit, on the course of DPN. Methods. The study included 20 patients with type 2 diabetes mellitus complicated by DPN of varying severity. Cocarnit was administered once a day intramuscularly at a dose of 2 ml for 9 days as part of complex therapy. Results. All patients had neuropathic pain of varying severity, which was confirmed by assessment using TSS, NSS and NDS scales. Against the background of the therapy, a significant decrease in pain and improvement in the quality of life was noted. After treatment, according to electroneuromyography, conduction along the motor and especially sensory nerves has improved. Conclusion. Cocarnit is an effective drug for the treatment of patients with diabetic distal sensorimotor polyneuropathy. The use of cockarnit, containing B vitamins, as well as triphosadenine and nicotinamide, is pathogenetically substantiated and effective in the complex treatment of patients with diabetic neuropathy.

diabetic neuropathy, diabetes mellitus, electroneuromyography, neuropathic pain, quality of life, Cocarnit